News

Gilead will integrate Interius, the first biotech to push an in vivo CAR-T therapy into the clinic, into its cell therapy ...
The Gilead HIV prevention shot , called Yevtugo, is highly effective, but its list price is $28, 218 a year in the U.S.
The Mount Gilead cross country boys picked up a team title Tuesday at the Upper Sandusky Icebreaker Invitational. The team scored 27 points to top the 14-team field. Columbus Grove was second with 48.
The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...
At a Television Critics Association panel on Jan 14., show creator Bruce Miller revealed that the writers foresaw Trump's ...
Interius is working on a more efficient way to deliver CAR-T therapy to patients. Unlock Digital Access for unlimited access to Inquirer.com and The Inquirer App, plus 5 articles per month to gift to ...
The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could potentially widen access to CAR-T treatment.
Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. Study Overview: Gilead Sciences, ...
The Handmaid's Tale got people talking right from the start. The show began in 2017 and threw us into Gilead, a scary place where women lose their rights and their names.
Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access.
Gilead Sciences agreed to buy Interius BioTherapeutics, a privately held biotechnology company developing in-vivo CAR therapeutics, for $350 million. Gilead on Thursday said the deal complements the ...
Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...